CO2022014258A2 - Moléculas de ácido nucleico interferente corto (sina, por sus siglas en inglés) modificadas y usos de estas - Google Patents
Moléculas de ácido nucleico interferente corto (sina, por sus siglas en inglés) modificadas y usos de estasInfo
- Publication number
- CO2022014258A2 CO2022014258A2 CONC2022/0014258A CO2022014258A CO2022014258A2 CO 2022014258 A2 CO2022014258 A2 CO 2022014258A2 CO 2022014258 A CO2022014258 A CO 2022014258A CO 2022014258 A2 CO2022014258 A2 CO 2022014258A2
- Authority
- CO
- Colombia
- Prior art keywords
- molecules
- nucleic acid
- short interfering
- interfering nucleic
- sin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986150P | 2020-03-06 | 2020-03-06 | |
| US202063109196P | 2020-11-03 | 2020-11-03 | |
| PCT/US2021/021199 WO2021178885A1 (en) | 2020-03-06 | 2021-03-05 | Modified short interfering nucleic acid (sina) molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014258A2 true CO2022014258A2 (es) | 2022-12-30 |
Family
ID=75278356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014258A CO2022014258A2 (es) | 2020-03-06 | 2022-10-05 | Moléculas de ácido nucleico interferente corto (sina, por sus siglas en inglés) modificadas y usos de estas |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220364096A1 (https=) |
| EP (1) | EP4121533A1 (https=) |
| JP (1) | JP2023515664A (https=) |
| KR (1) | KR20220163960A (https=) |
| CN (1) | CN115485384A (https=) |
| AU (1) | AU2021230601A1 (https=) |
| BR (1) | BR112022017287A2 (https=) |
| CA (1) | CA3170466A1 (https=) |
| CL (1) | CL2022002379A1 (https=) |
| CO (1) | CO2022014258A2 (https=) |
| GE (2) | GEAP202416053A (https=) |
| IL (1) | IL296045A (https=) |
| MX (1) | MX2022011012A (https=) |
| PE (1) | PE20221578A1 (https=) |
| PH (1) | PH12022552163A1 (https=) |
| TW (1) | TW202208625A (https=) |
| WO (1) | WO2021178885A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090720A1 (ru) * | 2017-09-14 | 2020-07-07 | Янссен Байофарма, Инк. | ПРОИЗВОДНЫЕ GalNAc |
| PE20221578A1 (es) * | 2020-03-06 | 2022-10-06 | Aligos Therapeutics Inc | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas |
| JP2023548031A (ja) | 2020-10-21 | 2023-11-15 | アリゴス セラピューティクス インコーポレイテッド | 二環式化合物 |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| WO2023224979A1 (en) * | 2022-05-16 | 2023-11-23 | University Of Massachusetts | Optimized sirna scaffolds |
| CN119421887A (zh) * | 2022-06-14 | 2025-02-11 | 大睿生物医药科技(上海)有限公司 | 环膦酸酯修饰的核苷酸 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| EP4654973A1 (en) * | 2023-01-26 | 2025-12-03 | Aligos Therapeutics, Inc. | Hepatitis b combination therapies |
| EP4665852A1 (en) * | 2023-02-14 | 2025-12-24 | Basecure Therapeutics | Modified double stranded rna agents |
| WO2024254091A1 (en) * | 2023-06-05 | 2024-12-12 | Empirico Inc. | Treatment of fgg related diseases and disorders |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| CN117024485B (zh) * | 2023-08-11 | 2026-02-13 | 江苏申基生物科技有限公司 | 一种2’-OMe腺苷的合成方法 |
| WO2025096970A2 (en) * | 2023-11-03 | 2025-05-08 | Basecure Therapeutics Llc | Modified oligonucleotides and methods of use thereof |
| WO2025104032A1 (en) | 2023-11-14 | 2025-05-22 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025201529A1 (en) * | 2024-03-29 | 2025-10-02 | Ractigen Therapeutics | Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof |
| US20250368996A1 (en) | 2024-05-14 | 2025-12-04 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN120796266A (zh) * | 2024-07-08 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 一种降低hbv基因表达的反义寡核苷酸及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002944A1 (en) * | 2007-06-22 | 2008-12-31 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| CN102753187A (zh) * | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| EA024762B9 (ru) * | 2011-06-30 | 2017-04-28 | Эрроухэд Рисерч Корпорейшн | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| SI3366775T2 (sl) * | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| CN106103463B (zh) * | 2014-02-18 | 2018-11-30 | 国立大学法人大阪大学 | 桥连型核苷和核苷酸 |
| AU2016306275A1 (en) * | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| KR20180095843A (ko) * | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| EP3387129A1 (en) * | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| DK3607069T3 (da) * | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| DK3719128T3 (da) * | 2017-12-01 | 2025-03-03 | Suzhou Ribo Life Science Co Ltd | Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| MX2020011570A (es) * | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| PE20211783A1 (es) | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| PE20221578A1 (es) * | 2020-03-06 | 2022-10-06 | Aligos Therapeutics Inc | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas |
-
2021
- 2021-03-05 PE PE2022001900A patent/PE20221578A1/es unknown
- 2021-03-05 MX MX2022011012A patent/MX2022011012A/es unknown
- 2021-03-05 CA CA3170466A patent/CA3170466A1/en active Pending
- 2021-03-05 GE GEAP202416053A patent/GEAP202416053A/en unknown
- 2021-03-05 CN CN202180032666.3A patent/CN115485384A/zh active Pending
- 2021-03-05 US US17/194,079 patent/US20220364096A1/en active Pending
- 2021-03-05 TW TW110108015A patent/TW202208625A/zh unknown
- 2021-03-05 PH PH1/2022/552163A patent/PH12022552163A1/en unknown
- 2021-03-05 AU AU2021230601A patent/AU2021230601A1/en active Pending
- 2021-03-05 BR BR112022017287A patent/BR112022017287A2/pt unknown
- 2021-03-05 JP JP2022552538A patent/JP2023515664A/ja active Pending
- 2021-03-05 EP EP21715377.4A patent/EP4121533A1/en active Pending
- 2021-03-05 KR KR1020227034100A patent/KR20220163960A/ko active Pending
- 2021-03-05 GE GEAP202116053A patent/GEP20257742B/en unknown
- 2021-03-05 WO PCT/US2021/021199 patent/WO2021178885A1/en not_active Ceased
- 2021-03-05 IL IL296045A patent/IL296045A/en unknown
-
2022
- 2022-02-15 US US17/672,268 patent/US11549110B2/en active Active
- 2022-09-01 CL CL2022002379A patent/CL2022002379A1/es unknown
- 2022-10-05 CO CONC2022/0014258A patent/CO2022014258A2/es unknown
- 2022-11-29 US US18/059,561 patent/US20230332153A1/en active Pending
-
2023
- 2023-07-28 US US18/361,363 patent/US12129469B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12129469B2 (en) | 2024-10-29 |
| CL2022002379A1 (es) | 2023-07-28 |
| TW202208625A (zh) | 2022-03-01 |
| GEAP202416053A (en) | 2024-10-10 |
| WO2021178885A1 (en) | 2021-09-10 |
| US20220177888A1 (en) | 2022-06-09 |
| AU2021230601A2 (en) | 2022-10-20 |
| CA3170466A1 (en) | 2021-09-10 |
| BR112022017287A2 (pt) | 2022-11-16 |
| US11549110B2 (en) | 2023-01-10 |
| EP4121533A1 (en) | 2023-01-25 |
| US20230365970A1 (en) | 2023-11-16 |
| JP2023515664A (ja) | 2023-04-13 |
| CN115485384A (zh) | 2022-12-16 |
| PH12022552163A1 (en) | 2024-01-29 |
| PE20221578A1 (es) | 2022-10-06 |
| KR20220163960A (ko) | 2022-12-12 |
| IL296045A (en) | 2022-10-01 |
| US20230332153A1 (en) | 2023-10-19 |
| GEP20257742B (en) | 2025-03-10 |
| AU2021230601A1 (en) | 2022-10-06 |
| US20220364096A1 (en) | 2022-11-17 |
| MX2022011012A (es) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014258A2 (es) | Moléculas de ácido nucleico interferente corto (sina, por sus siglas en inglés) modificadas y usos de estas | |
| MX2024002782A (es) | Moleculas modificadas de acido nucleico de interferencia corto (anic) y usos de las mismas. | |
| AR059433A1 (es) | Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas | |
| Fouquerel et al. | Oxidative guanine base damage regulates human telomerase activity | |
| MX2019002339A (es) | Analogos de 4'-fosfato y oligonucleotidos que los comprenden. | |
| MX2019012280A (es) | Composiciones dirigidas. | |
| MX2024003157A (es) | Composiciones moduladoras de inhibina subunidad beta e (inhbe) y metodos de uso de las mismas. | |
| PE20241933A1 (es) | Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt) | |
| PT2902406T (pt) | Inibição mediada por interferência de arn de expressão génica usando ácido nucleico de interferência pequeno (sian) | |
| BR0115814A (pt) | Moléculas de rna pequenas mediando interferência de rna | |
| CL2021001552A1 (es) | Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop | |
| DK1296713T3 (da) | Immunstimulerende oligodeoxynukleotider | |
| CL2022000825A1 (es) | Modificaciones químicas de arn pequeño de interferencia con contenido mínimo de flúor | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| CL2017002608A1 (es) | Agentes nucleósidos para la reducción de la actividad perjudicial de los genes que contienen repeticiones de nucleótidos extendidas. | |
| CO2025014055A2 (es) | Composiciones y métodos para la inhibición de la expresión de genes de la subunidad beta e de la inhibina (inhbe) | |
| MX2019014415A (es) | Compuesto monomerico de acido nucleico modificado y analogo de acido oligonucleico. | |
| WO2017218967A3 (en) | Stilbenoid prenyltransferases from plants | |
| MX2022009026A (es) | Composiciones de agentes de arni de cinasa de repeticion rica en leucina 2 (lrrk2) y metodos de uso de las mismas. | |
| CO2023018579A2 (es) | Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina (lrrk2 ) y métodos de uso de estas | |
| CL2022001481A1 (es) | Composiciones de ácidos nucleicos | |
| MX2023005138A (es) | Conjugados dirigidos que comprenden arnpi modificado. | |
| CO2023018656A2 (es) | Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos | |
| CL2021002842A1 (es) | Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas | |
| CO2022004857A2 (es) | Molécula de ácido nucleico para el tratamiento de la trombocitopenia y uso de la misma |